Sugi Predict

Sugi Predict / Compounds / SCHEMBL4774374

SCHEMBL4774374

SCHEMBL4774374

CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)cc1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ AGTR2 P50052 2/20 0.57
▸ ABCB11 O95342 1/20 0.57
▸ EGFR P00533 1/20 0.57
▸ ERBB2 P04626 1/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ ADORA3 P0DMS8 1/20 0.57
▸ CYP2C9 P11712 1/20 0.57
▸ ADRB3 P13945 1/20 0.57
▸ ADRA2B P18089 1/20 0.57
▸ SLC6A2 P23975 1/20 0.57
▸ TBXAS1 P24557 1/20 0.57
▸ HTR2C P28335 1/20 0.57
▸ AGTR1 P30556 1/20 0.57
▸ PPARG P37231 1/20 0.57
▸ HTR2B P41595 1/20 0.57
▸ PDE3A Q14432 1/20 0.57
▸ LTB4R2 Q9NPC1 1/20 0.57
▸ EDNRA P25101 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4791671 0.93 AGTR2 (0.51) AGTR2ABCB11EGFRERBB2CYP3A4
SCHEMBL4764423 0.93 EDNRA (0.48) AGTR2ABCB11EGFRERBB2CYP3A4
SCHEMBL4774383 0.93 EDNRA (0.48) AGTR2ABCB11EGFRERBB2CYP3A4
SCHEMBL4771827 0.90 EDNRA (0.58) EDNRA
SCHEMBL4763879 0.89 EDNRA (0.63) AGTR2ABCB11EGFRERBB2CYP3A4
SCHEMBL4770094 0.84 EDNRA (0.56) AGTR1EDNRA
SCHEMBL27541742 0.83 EDNRA (0.53) AGTR2ABCB11EGFRERBB2CYP3A4
SCHEMBL7847923 0.83 EDNRA (0.61) AGTR2AGTR1EDNRA
SCHEMBL4769543 0.83 EDNRA (0.56) AGTR2AGTR1EDNRA
SCHEMBL4769621 0.83 EDNRA (0.53) AGTR2AGTR1EDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2002837-A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2008-12-17 — — EP claimed
US-20040127515-A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists PHARMACOPEIA, LLC 2004-07-01 — — US claimed
US-20040106833-A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists PHARMACOPEIA, LLC 2004-06-03 — — US claimed
US-20020143024-A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists PHARMACOPEIA, LLC 2002-10-03 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127515-A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists EDNRB, AGTR2, EDNRA AGTR2 2/4885ABCB11 1057/4885EGFR 227/4885
US-20020143024-A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists EDNRB, AGTR2, EDNRA AGTR2 2/4885ABCB11 1057/4885EGFR 227/4885
US-20040106833-A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists EDNRB, AGTR2, EDNRA AGTR2 2/4885ABCB11 1057/4885EGFR 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.